3B BlackBio Dx Ltd (532067)
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, 3B BlackBio's revenue was ₹33.5 Cr (+50.7% year on year, -5.5% on the previous quarter), and net profit ₹9.0 Cr (-29.0% year on year); the operating margin was 25.4%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹33.5 | +50.7% | -5.5% |
| Operating profit | ₹8.5 | -28.0% | +0.4% |
| Net profit | ₹9.0 | -29.0% | -8.5% |
| EPS (₹) | 10.48 | -28.6% | -5.9% |
| Operating margin | 25.4% | — | — |
📢 Recent Corporate Announcements
3B BlackBio Dx Limited reported the conclusion of a one-on-one analyst/investor meeting with Param Capital, Mumbai, held on August 29, 2026, from 13:00 to 14:00 hrs IST. The company confirmed that discussions were based entirely on publicly available information, reiterating the Q1 FY27 investor presentation previously submitted on August 13, 2026. No unpublished price sensitive information (UPSI) was shared during the meeting.
- Meeting conducted one-on-one with Param Capital, Mumbai on August 29, 2026
- Interaction took place between 13:00 hrs and 14:00 hrs India Time
- Discussions strictly reiterated details from the Q1 FY27 investor presentation dated August 13, 2026
- No unpublished price sensitive information (UPSI) was disclosed
3B BlackBio Dx Limited has scheduled a one-on-one virtual analyst/investor meeting with Param Capital, Mumbai on Saturday, August 29, 2026, at 13:00 hrs IST. The interaction will reference the previously filed Q1-FY27 investor presentation dated August 13, 2026. The company confirmed that only publicly available information will be discussed with no unpublished price-sensitive information shared.
- One-on-one virtual interaction scheduled with Param Capital, Mumbai
- Meeting date set for Saturday, August 29, 2026, at 13:00 hrs IST
- Discussion based on existing Q1-FY27 investor presentation filed on August 13, 2026
3B BlackBio Dx reported a consolidated revenue of ₹33.49 Cr for Q1 FY27, a 50.6% increase from ₹22.23 Cr in Q1 FY26. This growth was primarily driven by the inclusion of Coris BioConcept, which contributed ₹8.63 Cr to the top line. However, consolidated PAT declined 29% YoY to ₹8.98 Cr, as Coris reported a negative EBITDA of ₹3.52 Cr. The standalone Indian Molecular Diagnostics (MDx) business remains healthy, growing 17.4% YoY in revenue to ₹23.43 Cr with a PAT of ₹13.68 Cr.
- Consolidated revenue increased to ₹33.49 Cr in Q1 FY27 from ₹22.23 Cr in Q1 FY26
- Coris BioConcept acquisition contributed ₹8.63 Cr to revenue but had a negative EBITDA of ₹3.52 Cr
- Standalone MDx revenue (excluding Coris) grew 17.4% YoY to ₹23.43 Cr
- Export sales for MDx reached ₹5.96 Cr in Q1 FY27 compared to ₹4.31 Cr in Q1 FY26
- Company maintains a ~15% market share in the Indian Molecular Diagnostics industry valued at ₹500-600 Cr
3B BlackBio Dx reported a strong 50.6% YoY growth in consolidated revenue to ₹33.49 Cr for Q1 FY27. However, consolidated PAT declined by 29% YoY to ₹8.98 Cr, significantly impacted by a 384% surge in employee benefit expenses and a 188% rise in other expenses. A key observation is that standalone PAT (₹14.11 Cr) was substantially higher than consolidated PAT, indicating that international subsidiaries or recent acquisitions are currently operating at a loss.
- Consolidated Revenue from operations increased 50.6% YoY to ₹33.49 Cr from ₹22.23 Cr.
- Consolidated PAT fell 29% YoY to ₹8.98 Cr compared to ₹12.64 Cr in the same quarter last year.
- Employee benefit expenses surged to ₹8.55 Cr from ₹1.77 Cr YoY, reflecting expansion and integration costs.
- Standalone PAT of ₹14.11 Cr outperformed the consolidated figure by ₹5.13 Cr, highlighting subsidiary-level drag.
- Other expenses rose to ₹8.87 Cr, driven by IVDR regulatory registration costs and international trade fair participation.
3B BlackBio Dx reported a strong 50.6% YoY growth in consolidated revenue to ₹33.49 Cr for Q1 FY27, primarily fueled by the Diagnostic Kits segment which reached ₹32.06 Cr. Despite the top-line surge, Consolidated Profit Before Tax (PBT) declined 16.6% YoY to ₹13.22 Cr, impacted by higher operational and regulatory costs related to IVDR registration. Standalone Net Profit showed a 13.2% increase to ₹14.11 Cr. The Agrochemicals business continues to shrink, contributing only ₹1.43 Cr to the top line as the company pivots toward molecular diagnostics.
- Consolidated Revenue from operations rose to ₹33.49 Cr, a 50.6% increase from ₹22.23 Cr in Q1 FY26
- Diagnostic Kits segment revenue grew 60.6% YoY to ₹32.06 Cr, now comprising 95.7% of total revenue
- Consolidated PBT decreased to ₹13.22 Cr from ₹15.86 Cr in the same quarter last year
- Standalone Other Expenses increased by 49.2% to ₹3.20 Cr, cited for IVDR registration and trade fairs
- Agrochemical segment revenue fell 37% YoY to ₹1.43 Cr, reflecting the company's strategic pivot
3B BlackBio Dx Ltd has scheduled a board meeting for August 13, 2026, to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company enters this period with a TTM revenue of Rs 142 Cr and a strong operating margin of 40.0%. Investors will be monitoring if the company can sustain its high profitability and 15-20% growth target following the acquisition of Coris BioConcept. The trading window for designated persons remains closed until 48 hours after the results are announced.
- Board meeting scheduled for August 13, 2026, to approve Q1 FY27 results
- Trading window for equity shares closed from July 1, 2026, until August 15, 2026
- Company reported a TTM PAT of Rs 60 Cr as of the latest financial context
- Operating Profit Margin (OPM) stood at 40.0% for the trailing twelve months
3B BlackBio Dx Ltd (formerly Kilpest India Limited) has issued a formal reminder to shareholders holding shares in physical form to submit mandatory KYC details and nominations. This action follows the SEBI Master Circular dated February 6, 2026, aimed at streamlining investor services. Shareholders who fail to update their KYC details (excluding nomination) are restricted to receiving dividends only through electronic modes. The company has directed affected holders to submit specific forms (ISR-1, ISR-2, ISR-3, SH-13/14) to its Registrar and Transfer Agent, Adroit Corporate Services Private Limited.
- Mandatory compliance with SEBI Master Circular No. SEBI/HO/38/13/(4)2026-MIRSD-POD/I/4298/2026 dated February 6, 2026
- Requirement to furnish 9 specific particulars including PAN, Bank details, and Nomination status
- Dividends for physical shareholders to be paid only via electronic mode effective from April 1, 2024
- Submission of Form ISR-3 required for shareholders opting out of nomination
Financial Performance
Revenue Growth by Segment
Consolidated revenue grew 30.14% YoY to INR 96.47 Cr. Molecular Diagnostics (Standalone Non-COVID) revenue grew 37.66% YoY to INR 78.13 Cr, while Agrochemicals revenue declined 10.95% YoY to INR 12.19 Cr.
Geographic Revenue Split
International sales for the MDx standalone business grew 96.8% YoY to INR 17.10 Cr. The company exports to over 70 countries, with the UK subsidiary (TPE) serving as a key hub for Europe, LATAM, and Africa.
Profitability Margins
Operating Profit Margin improved to 51.94% (from 44.49% YoY). Net Profit Margin increased to 49.44% (from 43.31% YoY). Consolidated PAT grew 48.56% to INR 47.69 Cr.
EBITDA Margin
Consolidated EBITDA stood at INR 65.19 Cr, representing a margin of approximately 67.58%, up from 61.40% in the previous year (INR 45.51 Cr).
Capital Expenditure
Not explicitly disclosed as a future Cr figure, but 42% of the current gross block is already invested in R&D infrastructure.
Credit Rating & Borrowing
The company is debt-free (Debt-Equity 0.00). Historical interest coverage was 1.77x (FY17), but current high profitability and zero debt suggest negligible borrowing costs.
Operational Drivers
Raw Materials
PCR Enzymes, Mastermix, reagents, and technical grade chemicals for pesticides (Insecticides, Fungicides).
Import Sources
Imports critical reagents and disposables; UK subsidiary provides 'Made in UK' products. Specific source countries for raw materials are not explicitly listed beyond the UK/Europe context.
Capacity Expansion
The Manchester facility integrates sales, marketing, and R&D. The company is continuously expanding into next-generation molecular diagnostic technologies. Specific MT/Unit capacity figures are not disclosed.
Raw Material Costs
Not disclosed as a specific % of revenue, but identified as a key risk factor for margins.
Manufacturing Efficiency
Successfully scaled up production to meet market requirements for molecular diagnostics. 42% of gross block is in R&D, supporting high-efficiency production of specialized kits.
Logistics & Distribution
Distribution costs are managed through optimized Incoterms and diversified freight modes, though specific % of revenue is not disclosed.
Strategic Growth
Expected Growth Rate
15-20%
Growth Strategy
Growth will be driven by the 'Reagent-Rental' model to secure recurring revenue (targeting 20-25% of total), the acquisition of Coris BioConcept to enter the Lateral Flow market, and expanding the TRUPCR portfolio into NGS and unique panels. The company also aims for 20-25% growth in international markets by leveraging its ISO-certified UK facility and 'Made in UK' branding.
Products & Services
Molecular diagnostic kits (TRUPCR®) for TB, HPV, Hepatitis, BCR-ABL; Agrochemicals including Insecticides (Bheem), Fungicides, and Plant Growth Regulators (Frutofix).
Brand Portfolio
TRUPCR, Bheem, Pradhan, Katerphos-Plus, Katerphose-Super, Baaz, Frutofix, Aum Flower.
New Products/Services
Launching unique panels in qPCR and NGS; expanding into Lateral Flow Immunoassays following the Coris BioConcept acquisition to capture high-growth segments.
Market Expansion
Targeting 20-25% growth in international business for FY 2025-26, focusing on LATAM, Africa, and Europe through the UK subsidiary.
Market Share & Ranking
12-15% market share in the Indian Molecular Diagnostics industry, which is valued at INR 350-450 Cr.
Strategic Alliances
Joint Venture with 2B BlackBio S.L. Spain and Biotools B&M Labs S.A. Spain (KIL holds 85.50% stake). Recently acquired Coris BioConcept SRL, Belgium to expand the IVD portfolio.
External Factors
Industry Trends
The Indian MDx industry is growing at 8-10% CAGR. There is a significant shift from COVID-19 testing to specialized molecular diagnostics (Oncology, Infectious Diseases). 3B BlackBio is positioning itself as a leader with a 12-15% market share and a focus on high-margin non-COVID assays which grew 37.66% in FY25.
Competitive Landscape
Facing increased competition in the MDx space as the market grows, but maintaining leadership through a broad product portfolio and technical excellence.
Competitive Moat
The company's moat is built on its 15-year R&D history and its 12-15% market share in India. The ISO 13485:2016 certification and the strategic Manchester facility provide a regulatory and branding advantage ('Made in UK') that facilitates easier access to 70+ global markets compared to domestic-only competitors.
Macro Economic Sensitivity
Sensitive to India's GDP growth (6.5% in FY25) and global inflation. A surge in inflation due to geopolitical conflicts could impact raw material pricing and consumer spending on healthcare.
Consumer Behavior
Increasing adoption of evidence-based treatments and precision diagnostics in India, supported by an aging population and better healthcare access.
Geopolitical Risks
Geopolitical disruptions in Eastern Europe and the Middle East are identified as primary risks affecting global inflation and supply chain stability.
Regulatory & Governance
Industry Regulations
Compliance with ISO 13485:2016 and health authority requirements for registration, safety, and labeling across 70+ countries.
Environmental Compliance
Mitigates risks through routine spill/effluent monitoring and emergency drills to reinforce an EHS-first culture. Specific ESG compliance costs in INR are not disclosed.
Taxation Policy Impact
Provision for tax in FY25 was INR 16.31 Cr on a consolidated PBT of INR 64.00 Cr, implying an effective tax rate of approximately 25.48%.
Legal Contingencies
The independent auditor's report confirms compliance with the Companies Act and SEBI regulations. No specific pending litigation values (INR) are mentioned.
Risk Analysis
Key Uncertainties
Potential for regulatory shutdowns or fines if EHS standards are not met, and the impact of capital market volatility on liquidity, though the company is currently debt-free.
Geographic Concentration Risk
Revenue is diversified across India and 70+ international markets, reducing dependency on any single region.
Third Party Dependencies
Dependency on single-source suppliers for critical reagents is a noted risk.
Technology Obsolescence Risk
Mitigated by a strong R&D focus (42% of gross block) and expansion into NGS and Lateral Flow technologies.
Credit & Counterparty Risk
Receivables quality is managed through regular monitoring; high current ratio (7.11) suggests strong liquidity.
